

12 December 2023

## **US\$30m capital commitment secured from leading Luxembourg based investment group to underpin long-term expansion strategy**

*The Company envisages going public via traditional IPO in the coming quarters and utilising the new capital to unlock significant value for shareholders*

- **US\$30m commitment secured from Luxembourg-based investment group, GEM Global Yield LLC (“GEM”) – providing APP with exceptional financial flexibility to fast track its growth strategy**
- **GEM is a US\$3.4Bn, alternative investment group with offices in Paris, New York, and The Bahamas**
- **Funding can be accessed following listing of APP common stock on any exchange with continuous trading – plans to advance initiative underway with key milestones expected to be met in 2024**
- **Capital to be deployed towards scale up of Medical Kiwi, R&D, new product development and construction of an extraction plant in Fiji to fast track Hardie Health operating division**
- **Funds will be accessed via a share issue mechanism, under which GEM will subscribe for APP common stock at a 10% discount to the trading price at that time**
- **APP will control the timing and maximum amount of each drawdown under the facility and has no minimum subscription obligation – providing exceptional downside protection**
- **Facility can be drawn down multiple times over a three year period for any amount – unlocks exceptional long term financial flexibility for APP**
- **Follows extensive due diligence between APP and GEM, which highlighted potential for strategic partnership and validated Aether’s major market opportunity**

**New Zealand:** Medicinal research and nutraceutical wellbeing company **Aether Pacific Pharmaceuticals** (“Aether Pacific”, “APP” or “the Company”) is pleased to advise it has secured a US\$30m investment commitment from leading alternative investment group, GEM Global Yield LLC (“GEM”), which can be accessed following the Company’s successful listing on any global stock exchange which has continuous trading capabilities. The funding provides Aether Pacific with exceptional financial flexibility as it progresses its stated growth strategy.

Global Emerging Markets (“GEM”) is a US\$3.4Bn, alternative investment group with offices in Paris, New York, and The Bahamas. GEM manages a diverse set of investment vehicles focused on emerging markets and has completed over 560 transactions in 72 countries. Each investment vehicle has a different degree of operational control, risk-adjusted return, and liquidity profile. The family of funds and investment vehicles provide GEM and its partners with exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities, and select venture investments.

The equity facility follows an extensive due diligence process undertaken between the Company and GEM. Aether Pacific is confident that the US\$30m facility will provide it with the balance sheet strength to rapidly advance its leading medicinal product portfolio towards commercialisation.

The Company plans to deploy capital towards the scale-up of its 100%-owned NZ-based medicinal cannabis growing subsidiary, Medical Kiwi, alongside its growing pipeline of clinical trials and R&D initiatives to drive new product development.

Additional funds will also be earmarked to progress botanical extraction initiatives under APP's Hardie Health operating division, which is focused on the research, development and commercialisation of plant-based novel compounds for use across a range of applications. APP will also consider utilising the funding towards the construction and development of an extraction hub in Fiji to optimise its supply chain ahead of aggressive scale up.

Under the terms of the agreement, GEM will provide Aether Pacific with a share subscription facility of up to US\$30m for a three year term following the public listing of the Company's common stock on any exchange which provides continuous trading. Funds will be accessed via a share issue mechanism, under which GEM will subscribe for APP common stock at a 10% discount to the trading price at that time. APP will control the timing and maximum amount of each drawdown under the facility and has no minimum subscription obligation, providing exceptional financial flexibility and downside protection.

**Management commentary:**

**Aether Pacific Pharmaceuticals Chairman, Mr Aldo Miccio said:** *"To have secured this funding facility with a world-class investment group is a major milestone for the Company. It provides considerable validation of the Company's growth strategy and further highlights APP's opportunity to become a leading global provider of medicinal cannabis and other plant-based extracts.*

*"The investment commitment agreement follows an extensive due diligence period, which has given the Board and management confidence that GEM is the right funding partner for Aether Pacific at this critical time in the Company's growth trajectory. We look forward to advancing our listing efforts in the coming quarters and utilising the new capital to unlock value for shareholders."*

Details for the [Capital Market raise here](#) and [company information here](#).

**ENDS**

**About Aether Pacific:**

Aether Pacific Pharmaceuticals (formerly Medical Kiwi Ltd.) is the 100% owner of the business unit Medical Kiwi, which is focused on cultivation of medicinal cannabis plants. Aether Pacific Pharmaceuticals also operates other business units including the Pain Clinic and Hardie Health.

**About GEM:**

Global Emerging Markets ('GEM') is a US\$3.4Bn, alternative investment group with offices in Paris, New York, and The Bahamas. GEM manages a diverse set of investment vehicles focused on emerging markets and has completed over 560 transactions in 72 countries. Each investment vehicle has a different degree of operational control, risk-adjusted return, and liquidity profile. The family of funds and investment vehicles provide GEM and its partners with exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities, and select venture investments.

**For further information, please contact:**

**Aldo Miccio**



**AETHER PACIFIC**  
PHARMACEUTICALS

**Chairman – Aether Pacific Pharmaceuticals Ltd**

**Email:** [aldo.miccio@medicalkiwi.com](mailto:aldo.miccio@medicalkiwi.com)

**Mobile:** 00 61 421 497 138